

2025 Magnetic Resonance Imaging (MRI) Breast

Diagnostic Imaging

MRI-Breast-HH
Copyright © 2025 WNS (Holdings) Ltd.

Last Review Date: 09/09/2025
Previous Review Date: 04/11/2025
Guideline Initiated: 06/30/2019





A WNS COMPANY

Table of Contents

Magnetic Resonance Imaging (MRI) Breast	3
MRI Breast Related National Coverage Determination (NCD)/Local Coverage Determination (LCD)	3
Clinical Judgment	3
MRI General Contraindications	3
Preamble: Pediatric Diagnostic Imaging	3
MRI Breast Guideline	4
Chest Surveillance section	7
Bone Cancer Surveillance	7
Breast Cancer Surveillance	9
Esophageal and Esophagogastric Junction Cancer Surveillance	9
Mesothelioma: Pleural Surveillance	9
Non-Small Cell Lung Cancer Surveillance	9
Occult Primary Cancer Surveillance	10
Small Cell Lung Cancer Surveillance	10
Soft Tissue Sarcoma Surveillance	10
MRI Breast Summary of Changes	11
MRI Breast Procedure Codes	12
MRI Breast Definitions	12
MRI Breast References	15
Disclaimer section	18
Purpose	18
Clinician Review	18
Payment	18
Registered Trademarks (®/™) and Copyright (©)	19
National and Local Coverage Determination (NCD and LCD)	19
Background	19
Medical Necessity Codes	19



A WNS COMPANY

Magnetic Resonance Imaging (MRI) Breast

MRI Breast Related National Coverage Determination (NCD)/ Local Coverage Determination (LCD)

Please refer to <https://www.cms.gov/medicare-coverage-database/search.aspx> if applicable to the individual's health plan membership.

Type/ID Number	Title
NCD 220.2	MRI
LCD 33585	Breast Imaging: Breast Echography (Sonography)/Breast Ductography
LCD 33950	Breast Imaging: Mammography/Breast Echography (Sonography)/Breast MRI/ Ductography

Clinical Judgment

These medical policies are designed to provide clinical guidance and do not supplant a provider's independent professional judgment. Physicians retain full and independent authority to determine appropriate care based on each patient's individual clinical circumstances. Although services may be subject to documentation requirements, medical necessity review, or coverage limitations, nothing in this policy is intended to restrict or interfere with a physician's independent medical judgment.

MRI General Contraindications

MRI is contraindicated for **ANY** of the following

- Safety, related to clinical status (body mass index exceeds MRI capability, intravascular stents within recent 6 weeks)
References: [21] [8] [12]
- Safety, related to implanted devices (aneurysm clips, cochlear implant, implantable cardio-defibrillators, insulin pump, permanent pacemaker, spinal cord stimulator)¹
References: [21] [8] [12]

Preamble: Pediatric Diagnostic Imaging

HealthHelp's clinical guidelines for the Diagnostic Imaging program, are intended to apply to both adults and pediatrics (21 years of age or younger), unless otherwise specified within the criteria.

¹Some implanted devices that were once absolute contraindications to a MRI may now be accepted, including if the specific MRI is able to accommodate the device or the device itself is deemed safe for MRI.

MRI Breast Guideline

Magnetic resonance imaging (MRI) of the breast is considered medically appropriate when the documentation demonstrates **ANY** of the following:

1. Breast cancer detection screening when there is **NO** history of breast cancer and **ANY** of the following:
 - a. Breast cancer risk assessment (by validated tool [eg, Gail model, Tyrer-Cuzik risk model]) identifies a lifetime breast cancer development risk of 20% or more, begin annual screening 10 years earlier than youngest family member's age at diagnosis or age is 40 years and **NOT** before age is 25 years.
 - b. Cancer gene mutation risk is known, based on genetic testing, for **ANY** of the following:
 - i. Breast cancer (BRCA) 1/2 mutation is known, begin annual screening at age 25 years.
 - ii. BRCA mutation is known in first degree relative (child, parent, sibling), but **NOT** yet tested for BRCA gene, begin annual screening at age 25 years.
 - iii. Germline mutations (known to be predisposed to a high risk of breast cancer) are known, including **ANY** of the following:
 - A. Ataxia telangiectasia (ATM), begin screening at age 40 years
 - B. Bannayan-Riley-Ruvalcaba syndrome (BRRS), begin screening at age 35 years or 10 years before the earliest age of family member diagnosed with breast cancer
 - C. BRCA1 associated RING domain 1 (BARD1), begin screening at age 40 years
 - D. Cadherin 1 (CDH1), begin screening at age 30 years
 - E. Checkpoint kinase 2 (CHEK2), begin screening at age 40 years
 - F. Cowden syndrome (PTEN), begin screening at age 35 years or 10 years before earliest breast cancer diagnosis in family
 - G. Li-Fraumeni syndrome (TP53 mutation), begin screening between ages 20 years to 29 years or age of earliest diagnosed breast cancer in family
 - H. Neurofibromatosis 1 (NF1), begin screening at age 30 years and stop at age 50 years
 - I. Partner and localizer of BRCA2 (PALB2), begin screening at age 30 years

- J. Peutz-jeghers syndrome (STK11), begin screening at age 25 years
- c. Chest irradiation with extensive history (eg, lymphoma treatments between ages 10 years to 30 years), begin screening 8 years after radiation and **NOT** before age 25 years
- d. Lobular neoplasia (atypical ductal hyperplasia [ADH], atypical lobular hyperplasia [ALH], lobular carcinoma in situ [LCIS]) is known, based on biopsy or prior imaging, with high lifetime risk of 20% or greater; annual screening beginning at age of diagnosis but **NOT** before age 25 years.
- e. Lobular neoplasia (ADH, ALH, LCIS) is known, based on biopsy or prior imaging, with intermediate lifetime risk of 15% to 20% **AND** dense breast tissue is present on mammography; annual screening beginning at age of diagnosis but **NOT** before to age 25 years.
- f. Supplemental breast cancer screening for **ANY** of the following:
 - i. Average risk (less than 15% lifetime risk of breast cancer) with dense breasts
 - ii. High risk (eg, 20% or greater lifetime risk of breast cancer, first degree relative with genetic disposition to breast cancer if **NOT** tested, genetic predisposition to breast cancer, history of chest irradiation between ages 10 years and 30 years old), regardless of breast density
 - iii. Intermediate risk (eg, 15% to 20% lifetime risk of breast cancer, family history of breast cancer **WITHOUT** known genetic mutations such as BRCA 1/2, personal history of breast cancer, lobular neoplasia, atypical ductal hyperplasia) with dense breasts
- g. Transmasculine (female to male) person with reduction mammoplasty or **NO** chest surgery with **EITHER** of the following risks:
 - i. High risk (eg, genetic predisposition to breast cancer, first degree relative with genetic disposition to breast cancer if **NOT** tested, history of chest irradiation between ages 10 years and 30 years old, 20% or greater lifetime risk of breast cancer) and age 25 years or older
 - ii. Intermediate risk (eg, personal history of breast cancer, lobular neoplasia, atypical ductal hyperplasia or 15% to 20% lifetime risk of breast cancer) and age 30 years or older

References: [17] [10] [4] [23] [28] [18] [19] [32] [3] [7]

- 2. Cancer is known, based on biopsy or prior imaging, with **ANY** of the following:

- a. Axillary nodal adenocarcinoma, with unidentified primary tumor
- b. Breast cancer is known in a transmasculine (female to male) person, prior to neoadjuvant chemotherapy, to determine tumor size and extent within the breast.
- c. Initial staging, when prior imaging is non-diagnostic or indeterminate.
- d. Lobular carcinoma is invasive and physical exam, mammography **OR** ultrasound are non-diagnostic or indeterminate.
- e. Lobular neoplasia is biopsy proven.
- f. Surveillance annually for **ANY** of the following:
 - i. Breast cancer history **AND** diagnosis was prior to age 50 years.
 - ii. Breast cancer history **AND** mammography shows dense breast tissue
 - iii. Risk of new cancer or recurrence is high due to risk factors (eg, genetic, life-style, personal history of cancer).
- g. Treatment response monitoring at baseline, during and after cancer treatments

References: [17] [10] [4] [31] [15] [13] [2]

3. Cancer is suspected (eg, lump in breast, nipple discharge, pain, prior imaging is abnormal), and **ANY** of the following:
 - a. Breast imaging-reporting and data system (BI-RADS) 3 lesion is probably benign **AND** seen only on prior MRI, for follow-up. (***NOTE:** *when prior mammogram and ultrasound did **NOT** show abnormality*)
 - b. Breast cancer is suspected and **ALL** of the following:
 - i. Biopsy could **NOT** be performed (eg, single view on mammogram without ultrasound correlation).
 - ii. Physical examination is non-diagnostic or indeterminate (includes skin changes of suspected inflammatory breast cancer).
 - iii. Prior imaging (ultrasound, mammography) is non-diagnostic or indeterminate.
 - c. Lobular neoplasia (ADH, ALH, LCIS) is demonstrated on biopsy.

References: [17] [10] [4] [31] [6]

4. Mass, lesion or abnormality in breast for **ANY** of the following: [31]
 - a. Diagnostic mammogram or ultrasound is non-diagnostic or indeterminate **OR** findings are conflicting, when the finding is **NOT** a palpable or discrete mass.

- b. Mass, lesion, distortion or abnormality of the breast is known, based on physical exam, prior imaging, with history of breast cancer **AND** prior imaging is non-diagnostic or indeterminate.
- c. Nipple discharge (bloody or serous) is unilateral and spontaneous, with **NO** palpable mass **AND** conventional imaging (eg, breast ultrasound, diagnostic mammography) demonstrates BI-RADS 1 through 3.
- d. Nipple inversion is new, when prior mammogram and ultrasound are non-diagnostic or indeterminate **AND** biopsy **CANNOT** be performed.
- e. Paget's disease of the breast, with **NO** palpable mass and prior imaging is non-diagnostic or indeterminate.
- f. Phyllodes tumor is known, diagnosed by biopsy, to determine extent of disease, **AND** for surgical planning.

References: [17] [10] [4] [27] [20] [27] [14] [24]

- 5. Peri-procedural for **EITHER** of the following:
 - a. Pre-procedure evaluation within 30 days of planned breast surgery, to guide treatment plan or monitor neoadjuvant chemotherapy response prior to surgery
 - b. Post-procedural follow-up (within 90 days of procedure)

References: [17] [10] [4] [16] [22]

- 6. Silicone breast implant complication assessment for **ANY** of the following: (***NOTE: MRI is NOT indicated for evaluation of saline implant complications OR for asymptomatic silicone implants**)
 - a. Post-operative complications (eg, breast deformity, pain, swelling) are suspected **AND** prior imaging is non-diagnostic or indeterminate.
 - b. Rupture is suspected, asymptomatic **AND** mammogram **OR** breast ultrasound is abnormal, non-diagnostic or indeterminate.
 - c. Symptomatic (eg, capsular contracture, breast lumps, changes in breast shape), for silicone implant rupture detection

References: [17] [10] [4] [16]

Chest Surveillance section

Bone Cancer Surveillance

Bone cancer surveillance includes **ANY** of the following:

1. Chondrosarcoma surveillance for **ANY** of the following:
 - a. Atypical cartilaginous tumor surveillance with cross-sectional imaging (CT + contrast, MRI \pm contrast) every 6 to 12 months for 2 years, then annually as clinically indicated
 - b. Low-grade, extracompartmental appendicular tumor, grade I axial tumors or high-grade (grade II or III, clear cell or extracompartmental) tumors surveillance with **ALL** of the following:
 - i. Chest CT at least every 6 months for 5 years, then annually for at least 10 years, then if symptoms are new or progressing.
 - ii. MRI (\pm contrast) or CT (+ contrast) if symptoms are new or progressing.
2. Chordoma surveillance with **ALL** of the following:
 - a. Chest CT imaging every 6 months, annually for 5 years, then annually thereafter, then if symptoms are new or worsening.
 - b. Imaging of primary site, timing and modality (eg, MRI \pm CT [both + contrast]) if symptoms are new or progressing, up to 10 years
3. Ewing Sarcoma after primary treatment completed surveillance with **ALL** of the following:
 - a. Chest CT: every 3 months
 - b. Primary site imaging with MRI \pm CT (both + contrast), increase intervals after 24 months and after 5 years, annually, then if symptoms are new or progressing (indefinitely) (***NOTE: PET/CT [head-to-toe] is appropriate**)
4. Giant cell tumor of the bone surveillance with **ALL** of the following:
 - a. Chest CT or MRI imaging every 6 to 12 months for 4 years, then annually thereafter, then if symptoms are new or progressing
 - b. Surgical site imaging if symptoms are new or progressing (eg, CT and/or MRI, both with contrast)
5. Osteosarcoma surveillance with primary site and chest imaging (using same imaging that was done for initial work-up) for **ANY** of the following: (***NOTE: PET/CT [head-to-toe] is appropriate.**)
 - a. Image every 3 months for years 1 and 2
 - b. Image every 4 months for year 3
 - c. Image every 6 months for years 4 and 5
 - d. Image annually for year 6 and thereafter, then if symptoms are new or progressing

References: [5]

Breast Cancer Surveillance

Breast cancer: No imaging surveillance suggested

References: [11]

Esophageal and Esophagogastric Junction Cancer Surveillance

Esophageal and esophagogastric junction cancer surveillance includes **ANY** of the following²:

1. Adenocarcinoma, squamous cell carcinoma; imaging studies if symptoms are new or progressing
2. Tumor classification T1b^a (N0 on ultrasound) after endoscopic resection or ablation, imaging surveillance includes computed tomography (CT) chest and abdomen (+ contrast, unless **contraindicated**) every 6 months for the first 2 years and annually for up to 5 years
3. Tumor classification T1b or greater, any N^a or T1a N+, imaging surveillance includes esophagectomy performed with or **WITHOUT** adjuvant therapy then surveillance includes chest and abdomen CT (+ contrast, unless **contraindicated**) every 6 months for the first 2 years and annually for up to 5 years
4. Tumor classification any T and/or any N, with neoadjuvant chemotherapy **OR** chemoradiotherapy **AND** esophagectomy, with or **WITHOUT** adjuvant treatment, imaging surveillance includes chest and abdomen CT (+ contrast, unless **contraindicated**) every 6 months for up to 2 years, then annually for up to 5 years and EGD, then if symptoms are new or progressing
5. Tumor classification (pretreatment) N0 to N+, T1b to T4, T4b, with definitive chemoradiation (**WITHOUT** esophagectomy), surveillance imaging includes chest and abdomen CT (+ contrast unless **contraindicated**) every 3 to 6 months for the first 2 years and annually for up to 5 years

References: [1]

Mesothelioma: Pleural Surveillance

Mesothelioma: Pleural: No imaging surveillance suggested.

References: [25]

Non-Small Cell Lung Cancer Surveillance

Non-small cell lung cancer imaging surveillance includes **ANY** of the following:

²Routine esophageal/esophagogastric junction cancers are **NOT** recommended for cancer-specific surveillance, for more than 5 years after the end of treatment.

1. Stage I to stage II (primary treatment includes radiation therapy) **OR** stage III or stage IV (oligometastatic with all sites treated with definitive intent); follow-up with chest CT (\pm contrast) every 3 to 6 months for 3 years, followed by every 6 months for 2 years, then low-dose (- contrast) chest CT annually
2. Stage I to stage II (primary treatment includes surgery \pm chemotherapy); follow-up with chest CT (\pm contrast) every 6 months for 2 to 3 years, then low-dose (- contrast) chest CT annually

References: [26]

Occult Primary Cancer Surveillance

Occult primary cancer surveillance imaging for long-term surveillance includes diagnostic tests based on symptomatology.

References: [29]

Small Cell Lung Cancer Surveillance

Small cell lung cancer surveillance includes **ANY** of the following:

1. Brain magnetic resonance imaging MRI (preferred) or computed tomography (CT) (+ contrast) every 3 to 4 months for 1 year, then every 6 months for year 2, then if symptoms are new or progressing. (regardless of prophylactic cranial irradiation [PCI] status).
2. Chest CT (\pm CT abdomen and pelvis) every 2 to 6 months (more frequently in years 1 and 2, less frequently thereafter)
3. Fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT is **NOT** recommended for routine follow-up unless CT or MRI (+contrast) is **contraindicated or unavailable**.

References: [9]

Soft Tissue Sarcoma Surveillance

Soft tissue sarcoma surveillance includes **ANY** of the following: (***NOTE:** Use contrast imaging; for long term surveillance to minimize radiation exposure, MRI may be substituted.)

1. Desmoid tumor (aggressive fibromatosis) imaging surveillance includes computed tomography (CT) or magnetic resonance imaging (MRI) every 3 to 6 months for 3 years, then every 6 to 12 months thereafter
2. Extremity, trunk or head and neck, for long-term follow-up with **ANY** of the following:
 - a. Long-term follow-up with **ALL** of the following:
 - i. Chest CT imaging (- contrast) to detect asymptomatic distant recurrence

- ii. MRI for imaging of primary site
- b. Stage I tumors and **ALL** of the following:
 - i. Chest CT imaging (- contrast) every 6 to 12 months
 - ii. Post-operative baseline and periodic imaging of primary site with MRI or CT if MRI is **contraindicated or unavailable**.
- c. Stage II and III tumors and **ANY** of the following:
 - i. Baseline and periodic imaging of primary site
 - ii. Chest and other known sites of metastatic disease imaging (CT [- contrast] or X-ray) every 2 to 6 months for 2 to 3 years, then every 6 months to complete a total of 5 years, then annually.
 - iii. Post-operative reimaging to assess the primary tumor site and rule out metastatic disease (MRI or CT if MRI is **contraindicated or unavailable**).
- 3. Retroperitoneal/intra-abdominal, after management of primary disease imaging surveillance includes chest/abdomen/pelvis CT or MRI every 3 to 6 months for 3 years, then every 6 months for the next 2 years, then annually.

References: [30]

MRI Breast Summary of Changes

MRI Breast guideline had the following version changes from 2024 to 2025:

Table 1. 2025 MRI Breast Summary of Changes

Date	Type of Change	Summary
09/09/2025	Mid-Cycle	<ul style="list-style-type: none"> • Added examples throughout for clarity • Added parameters (underlined below) for clarity to the following: <ul style="list-style-type: none"> ▪ "Cancer gene mutation risk is known, <u>based on genetic testing</u>" ▪ "Cancer is known, <u>based on biopsy or prior imaging</u>" ▪ "Lobular neoplasia (atypical ductal hyperplasia [ADH], atypical lobular hyperplasia [ALH], lobular carcinoma in situ [LCIS]) is known, <u>based on biopsy or prior imaging, with high lifetime risk</u>" ▪ "Lobular neoplasia (ADH, ALH, LCIS) is known, <u>based on biopsy or prior imaging, with intermediate lifetime risk</u>" ▪ "Mass, lesion, distortion or abnormality of the breast is known, <u>based on physical exam</u>" under "Mass, lesion or abnormality in breast" • Added time frame for "Post-procedural follow-up" in "Pre-procedural" indication

Date	Type of Change	Summary
04/11/2025	Annual	<ul style="list-style-type: none"> Changed the following to keep in line with current evidence: <ul style="list-style-type: none"> Nipple discharge (bloody or serous) is unilateral and spontaneous, with NO palpable mass AND conventional imaging (eg, breast ultrasound, diagnostic mammography) is non-diagnostic or indeterminate to "demonstrates BI-RADS 1 through 3" under "Mass, lesion" Citations were updated per the evidence.

MRI Breast Procedure Codes

Table 1. MRI Breast Associated Procedure Codes

CODE	DESCRIPTION
77046	Magnetic resonance imaging, breast, without contrast material; unilateral
77047	Magnetic resonance imaging, breast, without contrast material; bilateral
77048	Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral
77049	Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral
0649T	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure); single organ
C8903	Magnetic resonance imaging with contrast, breast; unilateral
C8905	Magnetic resonance imaging without contrast followed by with contrast, breast; unilateral
C8906	Magnetic resonance imaging with contrast, breast; bilateral
C8908	Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral

MRI Breast Definitions

Adenocarcinoma is a type of cancer that originates in glandular epithelial cells, which are cells that line the inside of organs and produce secretions.

Ataxia Telangiectasia Mutated (ATM) gene refer to changes in a gene that causes a rare neurodegenerative, autosomal recessive disorder characterized by chromosome instability, radiosensitivity, immunodeficiency and a predisposition for cancer.

Atypical ductal hyperplasia is the accumulation of abnormal epithelial proliferative breast lesions that are not qualitatively or quantitatively abnormal enough to be classified as carcinoma in situ. Atypical hyperplasia is a premalignant condition and may occur in either ductal or lobular epithelium.

Atypical lobular hyperplasia is the accumulation of abnormal cells in a breast lobule (the milk-making parts of the breast).

Bannayan-Riley-Ruvalcaba syndrome (BRRS) is a rare genetic disorder that is present at birth and is characterized by a large head size (macrocephaly), pigmented spots (maculae) on the penis and benign tumors and tumor-like growths in the intestine called hamartomas.

Breast Imaging-Reporting and Data System (BI-RADS™) Classifications

Table 1. BI-RADS™ Categories

BI-RADS™ CATEGORY	DESCRIPTION
Category 0: Incomplete	Additional imaging evaluation needed or prior mammography unavailable
Category 1: Negative	Symmetrical and no masses, architectural distortions or suspicious calcifications
Category 2: Benign Finding	No probability of malignancy
Category 3: Probably Benign Finding - Short Interval Follow-up Suggested	Less than 2% probability of malignancy and short follow-up interval recommended
Category 4: Suspicious Abnormality - Biopsy Should Be Considered	2% to 94% probability of malignancy, consider biopsy
Category 5: Highly Suggestive of Malignancy - Appropriate Action Should Be Taken	More than 95% probability of malignancy and appropriate action recommended
Category 6: Known Biopsy-Proven Malignancy - Appropriate Action Should Be Taken	Malignancy known from biopsy and appropriate action recommended

Table 2. BI-RADS™ Breast Density Categories

BI-RADS™ BREAST DENSITY CATEGORY
Category A: Almost entirely fatty
Category B: Scattered Fibroglandular Densities
Category C: Heterogeneously Dense
Category D: Extremely Dense

BRCA 1 or 2 are sometimes called tumor suppressor genes that change into harmful mutations resulting in cancer, notably breast and ovarian cancers.

Cadherin 1 (CDH1) also known as E-cadherin, is a protein encoded by the CDH1 gene that plays a crucial role in cell adhesion, helping epithelial cells stick together to form organized tissues.

Capsular is relating to a membrane or sac enclosing a body part.

Checkpoint Kinase 2 (CHK2) is a tumor suppressor gene that produces the CHK2 protein. CHK2 is a serine-threonine kinase that is involved in DNA repair, cell cycle arrest and apoptosis.

Cowden syndrome is a genetic disorder characterized by multiple noncancerous, tumor-like growths called hamartomas and an increased risk of developing certain cancers.

Gail Model incorporates six breast cancer risk factors, namely: age, age at menarche, age at first live birth, number of breast biopsies, history of atypical hyperplasia, and number of first-degree relatives with breast cancers. It is for use in women with no history of breast cancer, ductal

carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). Other tools may be more appropriate for women with known mutations in BRCA1, BRCA2, or other hereditary syndromes associated with breast cancer. The calculator can be found at <https://www.mdcalc.com/calc/3647/gail-model-breast-cancer-risk>

Germline mutation is a genetic change in a body's reproductive cell (egg or sperm) that becomes incorporated into the DNA of every cell in the body of the offspring.

Indeterminate findings are inconclusive or insufficient for treatment planning.

Li-Fraumeni syndrome (TP53 mutation) is a rare familial syndrome that is characterized especially by a high risk of developing early breast cancer and sarcomas of soft tissue.

Lobular carcinoma in situ (LCIS) is a non-invasive breast lesion characterized by the proliferation of atypical lobular cells confined within the lobules without breaching the basement membrane, and it serves as a marker for increased risk of developing invasive breast cancer.

Lobular neoplasia is a benign condition that describes a group of atypical epithelial lesions in the breast. These lesions originate in the terminal duct lobular unit (TDLU) of the breast. They are characterized by the proliferation of small, uniform cells that do not infiltrate the mammary gland basement membrane.

Lymphoma is a type of blood cancer that affects the immune system. Lymphoma occurs when abnormal white blood cells, called lymphocytes, grow in the lymphatic system.

Magnetic resonance imaging (MRI) is a non-invasive diagnostic technique that produces computerized images of internal body tissues and is based on nuclear magnetic resonance of atoms within the body induced by the application of radio waves.

Mammogram is an X-ray of the breasts that can be used to screen for breast cancer or for diagnostic purposes. During a mammogram, the breasts are compressed between two firm surfaces to spread them out.

Mammoplasty is cosmetic surgery performed on the breasts and fall into three categories: breast augmentation, breast reduction and breast reconstruction.

Neoadjuvant treatment is treatment (such as chemotherapy or hormone therapy) administered before primary cancer treatment (such as surgery) to enhance the outcome of primary treatment.

Neurofibromatosis is a rare genetic disorder that causes benign tumors to grow on nerves and other parts of the body. There are three types of neurofibromatosis: neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2) and schwannomatosis.

Non-diagnostic is a result that does not lead to a confirmed diagnosis.

Partner and Localizer of BRCA2 (PALB2) is a partner gene and localizer of the BRCA2 gene that provides instructions to make a protein that works with the BRCA2 protein to repair damaged DNA and stop tumor growth.

Paget's disease of the breast is a rare form of breast cancer that typically presents as a scaly, sore, eroding, bleeding ulcer of the nipple and is associated with underlying ductal carcinoma in situ or invasive carcinoma.

Pediatric approximate ages are defined by the US Department of Health (USDH), the Food and Drug Administration (FDA), and the American Academy of Pediatrics (AAP) as the following:

1. Infancy, between birth and 2 years of age
2. Childhood, from 2 to 12 years of age
3. Adolescence, from 12 to 21 years of age, further defined by the AAP into:
 - a. Early (ages 11–14 years)
 - b. Middle (ages 15–17 years),
 - c. Late (ages 18–21 years)
 - d. Older ages may be appropriate for children with special healthcare needs.

Peutz-Jeghers syndrome (PJS) is a familial polyposis inherited as an autosomal dominant trait that is characterized by numerous polyps in the stomach, small intestine and colon along with melanin-containing spots on the skin and mucous membranes especially the lips and gums.

Phyllodes tumor is a rare breast tumor that starts in the connective (stromal) tissue of the breast.

Screening is the systematic application of a test or inquiry to identify individuals at sufficient risk of a specific disorder to warrant further investigation or direct preventive action, among persons who have not sought medical attention for symptoms of that disorder.

Surveillance in cancer is the ongoing, timely and systematic collection and analysis of information on new cancer cases, extent of disease, screening tests, treatment, survival and cancer deaths.

Transmasculine people were assigned female gender at birth and identify as male.

Tyrer-Cuzick model is a risk assessment tool that estimates a woman's likelihood of developing breast cancer in 10 years or over her lifetime. The model also estimates the likelihood of being a BRCA1 or BRCA2 mutation carrier. The calculator can be found at <https://ibis-risk-calculator.magview.com/>

Ultrasound is the diagnostic or therapeutic use of ultrasound and especially a noninvasive technique involving the formation of images used for the examination and measurement of internal body structures and the detection of bodily abnormalities.

MRI Breast References

- [1] Ajani, J.A., D'Amico, T.A., Yoon, H.H. (2025). Esophageal and Esophagogastric Junction Cancers Version 3.2025. *National Comprehensive Cancer Network*. Retrieved: June 2025. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf

- [2] Alaref, A., Hassan, A., . . . Jahan, N. (2021). Magnetic Resonance Imaging Features in Different Types of Invasive Breast Cancer: A Systematic Review of the Literature. *Cureus*, 13(3), e13854.
- [3] Berg, W.A., Rafferty, E.A., . . . Rahbar, H. (2021). Screening Algorithms in Dense Breasts: AJR Expert Panel Narrative Review. *American Journal of Roentgenology*, 216(2), 275-294.
- [4] Bevers, T.B., Neill, B.L., . . . Yeh, E. (2025). Breast Cancer Screening and Diagnosis Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf
- [5] Bierman, J.S., Hirbe, A., . . . Wustrack, R.L. (2025). Bone Cancer Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: June 2025. https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf
- [6] (2025). Breast Cancer in Females. *Clinical Key*. Retrieved: March 2025. https://www.clinicalkey.com/#!/content/clinical_overview/67-s2.0-866e25c5-15bf-4016-9ae0-fc9ae1a3e9e5#diagnostic-procedures-heading-20
- [7] Brown, A., Lourenco, A.P., . . . Moy, L. (2021). ACR Appropriateness Criteria Transgender Breast Cancer Screening. *Journal of the American College of Radiology*, 18(11S), S502-S515.
- [8] Carpenter, J.P., Litt, H. & Gowda, M. (2023). Magnetic Resonance Imaging and Arteriography. A.N. Sidawy (Eds.). *Rutherford's Vascular Surgery and Endovascular Therapy* (30). (pp. 336-394.e4). Philadelphia, PA: Elsevier, Inc.
- [9] Ganti, A.K.P., Loo, B.W., . . . Waqar, S.N. (2025). Small Cell Lung Cancer Version 4.2025. *National Comprehensive Cancer Network*. Retrieved: June 2025. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
- [10] Gegios, A.R., Peterson, M.S. & Fowler, A.M. (2023). Breast Cancer Screening and Diagnosis. *PET Clinics*, 18(4), 459-471.
- [11] Gradishar, W.J., Moran, M.S., . . . Young, J.S. (2025). Breast Cancer Version 4.2025. *National Comprehensive Cancer Network*. Retrieved: June 2025. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
- [12] Gupta, S.K., Ya'qoub, L., . . . Saeed, I.M. (2020). Safety and Clinical Impact of MRI in Patients with Non-MRI-conditional Cardiac Devices. *Radiology: Cardiothoracic Imaging*, 2(5), e200086.
- [13] Hayward, J.H., Linden, O.E., . . . Slanetz, P.J. (2022). ACR Appropriateness Criteria Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer. *The Journal of the American College of Radiology*. Retrieved: September 2023. <https://acsearch.acr.org/docs/3099208/Narrative>
- [14] Jiang, N., Zhong, L., . . . Li, X. (2017). Value of Conventional MRI Texture Analysis in the Differential Diagnosis of Phyllodes Tumors and Fibroadenomas of the Breast. *Breast Care*, 16(3), 283-290.

- [15] Le-Petross, H.T., Slanetz, P.J., . . . Moy, L. (2022). ACR Appropriateness Criteria Imaging of the Axilla. *Journal of the American College of Radiology*, 19(5S), S87-S113.
- [16] Lourenco, A.P., Moy, L., . . . Newell, M.S. (2018). ACR Appropriateness Criteria Breast Implant Evaluation. *Journal of the American College of Radiology*, 15(5S), S13-S25.
- [17] Loving, V.A., Kocher, M., . . . Spear, G.G. (2023). ACR PRACTICE PARAMETER FOR THE PERFORMANCE OF CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING (MRI) OF THE BREAST. *American College of Radiology*. Retrieved: March 2025. <https://gravitas.acr.org/PPTS/GetDocumentView?docId=6#>
- [18] Maniero, M.B., Moy, L., . . . Newell, M.S. (2017). ACR Appropriateness Criteria Breast Cancer Screening. *Journal of the American College of Radiology*, 14(11), S383-S390.
- [19] Mann, R.M., Athanasiou, A., . . . Kuhl, C.K. (2022). Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI). *European Radiology*, 32(6), 4036-4045.
- [20] Markarian, S. & Holmes, D.R. (2022). Mammary Paget's Disease: An Update. *Cancers*, 14(10), Article 2422.
- [21] Maralani, P.J., Schieda, N., . . . Weinreb, J. (2020). MRI safety and devices: An update and expert consensus. *Journal of Magnetic Resonance Imaging*, 51(3), 657-674.
- [22] Mehta, T.S., Lourenco, A.P., . . . Moy, L. (2022). ACR Appropriateness Criteria Imaging After Breast Surgery. *Journal of the American College of Radiology*, 19(11S), S341-S356.
- [23] Neill, B.L., Jochelson, M.S., . . . Slanetz, P.J. (2024). ACR Appropriateness Criteria Female Breast Cancer Screening: 2023 Update. *Journal of the American College of Radiology*, 21(6), S126-S143.
- [24] Ofri, A., Stuart, K.E., . . . O'Toole, S. (2022). Diagnosis and management of phyllodes tumours for the surgeon: An algorithm. *The Surgeon*, 20(6), e355-e365.
- [25] Riely, G.J., Wood, D.E., . . . Yau, E. (2025). Mesothelioma: Pleural Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: February 2025. https://www.nccn.org/professionals/physician_gls/pdf/meso_pleural.pdf
- [26] Riely, G.J., Wood, D.E., . . . Yau, E. (2025). Non-Small Cell Lung Cancer Version 4.2025. *National Comprehensive Cancer Network*. Retrieved: June 2025. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
- [27] Samreen, N., Madsen, L.B., . . . Heller, S.L. (2021). Magnetic resonance imaging in the evaluation of pathologic nipple discharge: indications and imaging findings. *The British Journal of Radiology*, 94(1120), Article 20201013.
- [28] (2024). Screening for Breast Cancer US Preventive Services Task Force Recommendation Statement. *US Preventive Task Force*. Retrieved: March 2025. <https://jamanetwork.com/journals/jama/fullarticle/2818283>
- [29] Stevenson, M.M., Bowles, D.W., . . . Wang, S. (2025). Occult Primary Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: February 2025. https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf

- [30] von Mehren, M., Kane, J.M., . . . Zimel, M. (2025). Soft Tissue Sarcoma Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: June 2025. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf
- [31] Wiechmann, L. & Friedlander, LC. (2022). Management of Radiographic Lesions of the Breast. *The Surgical Clinics of North America*, 102(6), 1031-1041.
- [32] Weinstein, S.P., Slanetz, P.J., . . . Moy, L. (2021). ACR Appropriateness Criteria Supplemental Breast Cancer Screening Based on Breast Density. *Journal of the American College of Radiology*, 18(11S), S456-S473.

Disclaimer section

Purpose

The purpose of the HealthHelp's clinical guidelines is to assist healthcare professionals in selecting the medical service that may be appropriate and supported by evidence to safely improve outcomes. Medical information is constantly evolving, and HealthHelp reserves the right to review and update these clinical guidelines periodically. HealthHelp reserves the right to include in these guidelines the clinical indications as appropriate for the organization's program objectives. Therefore the guidelines are not a list of all the clinical indications for a stated procedure, and associated Procedure Code Tables may not represent all codes available for that state procedure or that are managed by a specific client-organization.

Clinician Review

These clinical guidelines neither preempt clinical judgment of trained professionals nor advise anyone on how to practice medicine. Healthcare professionals using these clinical guidelines are responsible for all clinical decisions based on their assessment. All Clinical Reviewers are instructed to apply clinical indications based on individual patient assessment and documentation, within the scope of their clinical license.

Payment

The use of these clinical guidelines does not provide authorization, certification, explanation of benefits, or guarantee of payment; nor do the guidelines substitute for, or constitute, medical advice. Federal and State law, as well as member benefit contract language (including definitions and specific contract provisions/exclusions) take precedence over clinical guidelines and must be considered first when determining eligibility for coverage. All final determinations on coverage and payment are the responsibility of the health plan. Nothing contained within this document can be interpreted to mean otherwise.

Registered Trademarks (®/™) and Copyright (©)

All trademarks, product names, logos, and brand names are the property of their respective owners and are used for purposes of information and/or illustration only. Current Procedural Terminology (CPT)[®]™ is a registered trademark of the American Medical Association (AMA). No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from HealthHelp.

National and Local Coverage Determination (NCD and LCD)



NOTICE

To ensure appropriate review occurs to the most current NCD and/or LCD, always defer to <https://www.cms.gov/medicare-coverage-database/search.aspx>.

Background

National Coverage Determinations (NCD) and Local Coverage Determinations (LCD) are payment policy documents outlined by the Centers for Medicare and Medicaid Services (CMS) and the government's delegated Medicare Audit Contractors (MACs) that operate regionally in jurisdictions.

CMS introduced variation between different jurisdictions/Medicare Audit Contractors (MACs) and their associated covered code lists with the transition to ICD 10. The variation resulted in jurisdictions independently defining how codes are applied for exclusions, limitations, groupings, ranges, etc. for the medical necessity indications outlined in the NCD and LCD. Due to this variation, there is an inconsistent use/application of codes and coverage determinations across the United States between the different MACs.

In addition, **WITHOUT** notice, CMS can change the codes that indicate medical necessity and the format of the coverage determinations/associated documents (eg, Articles). This is an additional challenge for organizations to keep up with ongoing, unplanned changes in covered codes and medical necessity indications.

Medical Necessity Codes

Due to the variation in code application between jurisdictions/MACs and that updates can happen without notification, HealthHelp is not able to guarantee full accuracy of the codes listed for any Coverage Determination, and advises that prior to use, the associated Coverage Determination Articles are reviewed to ensure applicability to HealthHelp's programs and any associated NCDs and LCDs.



A WNS COMPANY

For Internal Use Only:

11248 11249 11253 11282 11325 11328 11333 11349 11350 11351 11352 11354 11355 11356
11358 11359 11360 11361 11362 11365 11366 11367 11368 11369 11370 11374 11375 11394
11395 11396 11565